• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Intravenous Thrombolysis in Anticoagulated and Thrombocytopenic Ischemic Stroke Patients Does Not Increase the Risk of Intracerebral Hemorrhage (P4.271)
Conclusions:These data suggest that IV rt-PA can be safely administered in coagulopathic and thrombocytopenic patients. Although rates of sICH and mortality were similar to the NINDS cohort, caution may be needed to identify certain hemorrhagic risk factors. Routine exclusion of anticoagulated or thrombocytopenic patients is not supported and the use of IV rt-PA in these patients may increase the eligibility for acute stroke therapy, particularly at institutions where IA therapy is unavailable.Disclosure: Dr. Barazangi has received personal compensation for activities with Genentech. Dr. Sorensen has nothing to disclose. D...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Barazangi, N., Sorensen, S., Chen, C., Wong, C., Yee, A., Ke, M., Rose, J., Grosvenor, D., Bedenk, A., Fernandes, J., Tong, D. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research

Rapidly improving neurological deficit of stroke; case series in Academic institute, KAUH, Jeddah (P4.283)
Conclusions:Rapidly improving patient represent a challenge to whether tPA should be given. However, the good outcome with thrombolytic therapy observed in our study, will hopfuly support the decision to treat.Study Supported by: nonDisclosure: Dr. khoja has nothing to disclose. Dr. Alshaer has nothing to disclose. Dr. al-Turkistani has nothing to disclose. Dr. Al-Mekhalfi has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: khoja, a., Al-Shaer, D., al-Turkistani, a., Al-Mekhalfi, M. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research

Resident door to needle Analysis: A retrospective Chart rEview (RACE) (P4.285)
Conclusions:Recognition and token awards for neurology residents can lead to shorter DTN times which could, in turn, improve outcomes in AIS. However, this approach requires a continued review of diagnostic accuracy and adverse events to ensure quality of care is not compromised for the sake of speed.Disclosure: Dr. Patel has nothing to disclose. Dr. Mehta has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Patel, N., Mehta, S. Tags: Thrombolysis and Acute Evaluation in Ischemic Stroke Source Type: research

Hemorrhagic transformation of ischemic strokes: risk factors and prognostic implications (P4.291)
Conclusions:IV thrombolytic therapy, cardioembolic stroke and prior warfarin use were independent predictors of HT. PH2 was associated with increased risk of poor outcome at around 90 days and mortality at 90 days and 5 years.Disclosure: Dr. Cheung has nothing to disclose. Dr. Chan has nothing to disclose. Dr. Lee has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Cheung, R., Chan, K. H., Lee, R. Tags: In-Hospital Stroke Care Source Type: research

Getting to the Core of Stroke Care: Real Time Chart Review Improves Hospital Compliance with Core Measures (P6.269)
Conclusions:Real time chart review, utilization of a MQA, and alerting of providers is significantly more effective than a process utilizing retrospective chart review based on sampling and manual abstraction in increasing CM compliance. Implementation of these methods reduces CM deficiencies and leads to improved stroke care.Disclosure: Dr. Katsafanas has nothing to disclose. Dr. Furbeyre has nothing to disclose. Dr. Coppen has nothing to disclose. Dr. Hodges has nothing to disclose. Dr. Schnepel has nothing to disclose. Dr. Falk has nothing to disclose. Dr. Alonso has nothing to disclose. Dr. Tran has nothing to disclose...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Katsafanas, C., Furbeyre, J., Coppen, V., Hodges, W., Schnepel, L., Falk, D., Alonso, J., Tran, A., Northcut, M., Toback, A., Silliman, S. Tags: Cerebrovascular Disease Health Services Research Source Type: research

Acute Stroke Therapy in Infective Endocarditis - Case Series and Systematic Review (P6.295)
Conclusions:Endovascular thrombectomy alone appears to be safer than IV-tPA alone in the management of AIS in patients with IE.Disclosure: Dr. Marquardt has nothing to disclose. Dr. Cho has nothing to disclose. Dr. Zhang has nothing to disclose. Dr. Uchino has nothing to disclose. Dr. Wisco has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Marquardt, R., Cho, S.-M., Zhang, L., Uchino, K., Wisco, D. Tags: Cardiovascular Issues in Ischemic Stroke Source Type: research

Age, Gender and Racial Disparities in Acute Stroke Therapy in a Large Non-Academic Health System (P3.261)
Conclusions:We confirmed known disparities in ATT rates between PSC and AH. No disparity in age or gender were identified in this population. Racial disparity was problematic because of a small number of non-white patients and a number of patients with no racial data captured. Better racial data collection, analysis of access to care, and care process modeling might impact these findings.Disclosure: Dr. Taylor has nothing to disclose. Dr. Jones has received personal compensation for activities with Genentech as a speaker. Dr. Gosnell has nothing to disclose. Dr. Snyder has nothing to disclose. Dr. Schneider has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Taylor, R., Jones, R., Gosnell, J., Snyder, S., Schneider, A. Tags: Cerebrovascular Disease Epidemiology Source Type: research

Pattern of Utilization of Carotid Endarterectomy in Acute Ischemic Stroke Patients Undergoing Early Carotid Endarterectomy According to Severity of Neurological Deficits and Infarct Size (P5.277)
Conclusions:CEA was performed in ischemic stroke patients with minor or moderate infarction on CT scan with an acceptable rate of recurrent stroke and death and without any adverse functional outcome.Disclosure: Dr. Ahrar has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Saleem has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Ahrar, A., Qureshi, A., Saleem, M. Tags: SubAcute Interventional Therapies in Cerebrovascular Disease Source Type: research

Stroke Code Simulation Lab; Save Time Save Brain! (P2.375)
CONCLUSIONS: The stroke code simulation lab met its objectives of improving the neurology residents’ knowledge and experience managing stroke codes. It was perceived as a valuable exercise. Further data will determine if the stroke code simulation lab improves patient care.Disclosure: Dr. Mao has nothing to disclose. Dr. Zidan has nothing to disclose. Dr. Afzal has nothing to disclose. Dr. Cherukuri has nothing to disclose. Dr. Qadeer has nothing to disclose. Dr. Bradshaw has received research support from Cytokinetcs.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Mao, Y., Zidan, A., Afzal, U., Cherukuri, R., Qadeer, U., Bradshaw, D. Tags: Research Methodology and Education: Patient Safety and Quality Source Type: research

90 Day Outcome after Reperfusion Therapy of Stroke Patients with Baseline Disability: Unique Observations from Patients Treated on the Mobile Stroke Unit (P6.052)
Conclusion: In comparison to previously published data our analysis shows unfavorable outcome in the majority of patients with baseline disability who received thrombolytic therapy. The small sample size is a limitation to this analysis, and further studies are needed to assess if this subpopulation should be included in clinical trials assessing new therapies or modalities to deliver them.Disclosure: Dr. almaghrabi has nothing to disclose. Dr. Sarraj has nothing to disclose. Dr. Bowry has nothing to disclose. Dr. Parker has nothing to disclose. Dr. Yamal has nothing to disclose. Dr. Grotta has received personal compensati...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Almaghrabi, T., Sarraj, A., Bowry, R., Parker, S., Yamal, J.-M., Grotta, J. Tags: Prehospital Stroke Care and Uses of NIHSS Source Type: research

Multidisciplinary In Situ Mock Stroke Codes Improve Thrombolytic Delivery by Decreasing Door To Needle Times in a Comprehensive Stroke Center. (P6.086)
Conclusions: Door to needle time is reduced as a result of MSCs. MSCs should be routinely performed at CSCs to improve door to needle time and patient outcomes.Disclosure: Dr. Burshtein has nothing to disclose. Dr. Kapoor has nothing to disclose. Dr. Sorrentino has nothing to disclose. Dr. Michael has nothing to disclose. Dr. Carrazco has nothing to disclose. Dr. Wright has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Burshtein, R., Kapoor, A., Sorrentino, C., Michael, C., Carrazco, C., Wright, P. Tags: Cerebrovascular Disease and Interventional Neurology: Patient Safety and Quality Source Type: research

Is There a "Smoker's Paradox" in Acute Reperfusion Therapies? (P1.176)
Conclusions: Our study did not support presence of the "Smoker's Paradox" in AIS patients who receive IV or ET therapy. A rigorous adjustment for risk factors is likely to eliminate the paradoxical finding of more frequent favorable outcome in smokers who have not received tPA or ET.Disclosure: Dr. Arora has nothing to disclose. Dr. Sharipour has nothing to disclose. Dr. Donnelly has nothing to disclose. Dr. Shiue has nothing to disclose. Dr. Gadpaille has nothing to disclose. Dr. Sisson has nothing to disclose. Dr. Lyerly has nothing to disclose. Dr. Gropen has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Arora, K., Sharipour, R., Donnelly, J., Shiue, H., Gadpaille, A., Sisson, A., Lyerly, M., Gropen, T. Tags: Cerebrovascular Disease: Risk Factors and Prevention Source Type: research

Cost Effectiveness of Stent-Retriever Thrombectomy Compared with Intravenous Thrombolytic Therapy Alone in Acute Ischemic Stroke Patients (S47.005)
Conclusions: In acute ischemic stroke patients and major arterial occlusion, stent-retriever thrombectomy in addition to intravenous t-PA,is both cost effective and improves quality of life.Disclosure: Dr. Chaudhry has nothing to disclose. Dr. Ishfaq has nothing to disclose. Dr. Sivagnanam has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - February 7, 2016 Category: Neurology Authors: Chaudhry, S., Ishfaq, M., Sivagnanam, K., Qureshi, A. Tags: IV-tPA and Endovascular Therapy Source Type: research

Cerebral hemorrhage following thrombolytic therapy for stroke: Are neutrophils really neutral?
An ideal biomarker can accurately predict disease risk stratification. The longstanding link between inflammatory responses and atherosclerotic disease and vascular events suggests great promise for inflammatory measures as biomarkers in stroke and other vascular disease. Recent studies across multiple areas and disciplines have suggested that leukocytes, as an inflammatory marker, and specifically neutrophils, may hold promise in predicting poor outcomes in various cardiovascular diseases (e.g., heart failure, acute coronary syndromes, stable coronary artery disease), including stroke, as well as in neoplasms, infections,...
Source: Neurology - October 19, 2015 Category: Neurology Authors: Roever, L., Levine, S. R. Tags: All Cerebrovascular disease/Stroke, All epidemiology, Prevalence studies, Risk factors in epidemiology, Intracerebral hemorrhage EDITORIALS Source Type: research

Cyclosporine in acute ischemic stroke
Conclusions: Cyclosporine was generally not effective in reducing infarct size. However, a smaller infarct size was observed in patients with proximal cerebral artery occlusion and efficient recanalization. Classification of evidence: This study provides Class I evidence that in patients with an acute anterior-circulation stroke, thrombolysis plus IV cyclosporine does not significantly decrease 30-day MRI infarct volume compared with thrombolysis alone.
Source: Neurology - June 1, 2015 Category: Neurology Authors: Nighoghossian, N., Berthezene, Y., Mechtouff, L., Derex, L., Cho, T. H., Ritzenthaler, T., Rheims, S., Chauveau, F., Bejot, Y., Jacquin, A., Giroud, M., Ricolfi, F., Philippeau, F., Lamy, C., Turc, G., Bodiguel, E., Domigo, V., Guiraud, V., Mas, J.-L., Op Tags: Clinical trials Randomized controlled (CONSORT agreement), Class I, Infarction ARTICLE Source Type: research

Pages: 1  2  3